Tasha Arciello
Adult Health · Kingston, NYNPI 1750928578
Payments from drug & device makers
Across 153 payments — averaging $22.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$463
- AbbVie$339
- Novo Nordisk$297
- GSK$242
- Lilly USA, LLC$236
- AstraZeneca$177
- plus $2K from 33 others
What the payments were for
- Food & beverage$3,374100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 18 | $463 |
| AbbVie | 12 | $339 |
| Novo Nordisk | 12 | $297 |
| GSK | 12 | $242 |
| Lilly USA, LLC | 13 | $236 |
| AstraZeneca | 10 | $177 |
| Otsuka America Pharmaceutical, Inc. | 8 | $157 |
| Acadia Pharmaceuticals Inc | 7 | $127 |
| Mylan Specialty L.p. | 1 | $122 |
| Lundbeck LLC | 4 | $91 |
| Xeris Pharmaceuticals, Inc. | 4 | $84 |
| Neurocrine Biosciences, Inc. | 4 | $83 |
| Collegium Pharmaceutical, Inc. | 4 | $77 |
| Sumitomo Pharma America, Inc. | 4 | $71 |
| Bayer | 3 | $59 |
| Seqirus USA Inc | 3 | $57 |
| Amgen | 2 | $52 |
| E.r. Squibb & Sons, L.L.C. | 3 | $52 |
| Exact Sciences | 2 | $50 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $48 |
| Boehringer Ingelheim | 2 | $41 |
| Novartis | 2 | $41 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $40 |
| UCB, Inc. | 1 | $39 |
| Kowa Pharmaceuticals America, Inc. | 2 | $32 |
| Inspire Medical Systems, Inc. | 1 | $31 |
| Johnson & Johnson | 2 | $31 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $29 |
| Alkermes, Inc. | 1 | $23 |
| Sunovion Pharmaceuticals Inc. | 1 | $21 |
| Abbott | 1 | $20 |
| Sanofi Pasteur Inc. | 1 | $20 |
| IBSA Pharma Inc. | 1 | $19 |
| Dexcom, Inc. | 1 | $18 |
| Aimmune Therapeutics, Inc. | 1 | $18 |
| Astellas Pharma US Inc | 1 | $17 |
| Merck | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 1 | $17 |
| RGH Enterprises LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Yupelri$122
- Wegovy$115
- NURTEC ODT$106
How this compares
$3,374 in reported general payments places this provider in the 85th percentile of 3,828 adult health providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 121 | $58,651 |
| RybelsusSemaglutide | 27 | $53,514 |
| NuplazidPimavanserin Tartrate | 20 | $49,712 |
| XareltoRivaroxaban | 46 | $47,611 |
| JanuviaSitagliptin Phosphate | 37 | $32,249 |
| MounjaroTirzepatide | 18 | $28,460 |
| OzempicSemaglutide | 21 | $27,605 |
| JardianceEmpagliflozin | 35 | $26,006 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 37 | $23,685 |
| FarxigaDapagliflozin Propanediol | 11 | $14,253 |
| Xtampza ErOxycodone Myristate | 23 | $12,527 |
| Breo ElliptaFluticasone/Vilanterol | 22 | $10,729 |
| Incruse ElliptaUmeclidinium Bromide | 30 | $10,205 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 64 | $8,442 |
| Lagevrio (Eua)Molnupiravir | 12 | $5,993 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $297 | $81,11948 claims |
| PfizerEliquis | $463 | $58,651121 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta | $242 | $49,850100 claims |
| Acadia Pharmaceuticals IncNuplazid | $127 | $49,71220 claims |
| Johnson & JohnsonXarelto | $31 | $47,61146 claims |
| MerckJanuvia, Lagevrio (Eua) | $17 | $38,24349 claims |
| Lilly USA, LLCMounjaro | $236 | $28,46018 claims |
| Boehringer IngelheimJardiance | $41 | $26,00635 claims |
| AstraZenecaFarxiga | $177 | $14,25311 claims |
| Collegium Pharmaceutical, Inc.Xtampza Er | $77 | $12,52723 claims |
| AbbVieSynthroid | $339 | $1,79434 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,828 adult health providers in New York.
Other adult health in Kingston
- Marguerite CallahanNew York$1.4M
- Donna CatameroNew York$279K
- Kristen DurkinPort Jefferson Station$255K
- Katelyn McCormackAmherst$201K
- Mary CiechoskiBuffalo$200K
- Patricia LorussoLancaster$161K
- Jennifer FioriniGlens Falls$151K
- Tia AlbroRochester$142K
- Maria Gigante-BaggettEast Syracuse$92K
- Jane PattersonRochester$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.